Prasugrel is a thienopyridine that was approved by the US Food and Drug Administration (FDA) in combination with aspirin for the reduction of thrombotic events as well as stent thrombosis in patients with ACS who undergo PCI. This retrospective study aims to assess the frequency of inappropriate use of prasugrel and to emphasize that prasugrel still needs more attention as inappropriate use may result in significant morbidity.
Conflict(s) of Interest
The authors have no financial disclosures to declare and no conflicts of interest to report.
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
Amro, Ahmed; Mansoor, Kanaan; Amro, Mohammad; Sobeih, Amal; Aqtash, Obadah; Hirzallah, Hisham; Gabi, Alaa; Urella, Madhulika; Ahmed, Waseem; Shenouda, Sandra; and Sayyed, MD, Dr. Rameez
"Prasugrel Inappropriate Use in Patients Post-percutaneous coronary intervention (PCI). A Single Center Study,"
Marshall Journal of Medicine:
3, Article 8.
Available at: https://mds.marshall.edu/mjm/vol5/iss3/8